Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

IBA SA : TRANSPARENCY NOTIFICATION

IBA SA
Posted on: 12 Jan 18

IBA - TRANSPARENCY NOTIFICATION

Louvain-la-Neuve, Belgium, January 12, 2018, 17.35 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on January 12, 2018.

Reason for the notification Upwards crossing of the 3% threshold further to the acquisition of shares -and thus voting rights- held as loan collateral
Persons subject to the notification requirement IBA SA, issuer
Persons that dispose of voting rights Kempen Capital Management NV
Transaction date  01/01/2018
Threshold that is crossed (in %)   3%
Upwards crossing further to the acquisition of voting rights
Denominator  29 962 246
Voting rights (number)  900 174
Voting rights (%)  3,00%
Chain of control Van Lanschot Kempen N.V. < 100%> F. van Lanschot Banklers NV <100%> kempen & Co NV <100%> Kempen Capital Management NV. Kempen se réfère à la declaration d'indépendance (datée du 15 novembre 2017).
Additional information Kempen Capital Management NV appeals for Art. 11 of the (Transparency) Law (May 2, 2007), by which an exemption is acquired.

About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

For further information, please contact:

IBA

Stephanie Bauwin
Legal Counsel
+32 10 203 924
Stephanie.bauwin@iba-group.com

20180112 transparency Notification EN


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: IBA SA via GlobeNewswire
HUG#2161144
GlobeNewswire
globenewswire.com

Last updated on: 15/01/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.